PARAMUS, N.J.--(BUSINESS WIRE)--EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.
